GCAR, Eisai and UPMC, on Behalf of REMAP-CAP Investigator Network, Announce Eritoran’s Inclusion in REMAP-COVID, An Adaptive Clinical Trial to Test Interventions for Patients With Moderate and Severe ...
在重症监护病房（ICU），REMAP-CAP 平台试验的知情同意文件复杂难懂。研究人员开展共创并试点测试信息图以辅助 REMAP-CAP 同意过程的混合方法研究，成功开发信息图，试点测试达到部分可行性目标，为后续研究提供参考。 在医学研究的舞台上，知情同意环节至关 ...
针对糖皮质激素在重症社区获得性肺炎(CAP)治疗中的长期争议，REMAP-CAP平台试验通过创新性随机嵌入式多因素适应性设计，评估了7天氢化可的松静脉疗程的疗效。研究发现该方案不仅未能降低90天死亡率(调整后OR 1.52-1.63)，反而可能增加死亡风险，这与CAPE-COD试验 ...
The world’s largest trial of multiple interventions for critically ill adults with COVID-19 has simultaneously released results about two of its treatments, vitamin C and simvastatin LARKSPUR, Calif. ...
CHESTERBROOK, Pa., April 21, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with ...
It’s unlikely that adding an antiplatelet agent to anticoagulation will increase the number of organ support-free days in critically ill patients with COVID-19, although it’s possible that survival in ...
NovaBiotics' NM002 (cysteamine bitartrate) Under Investigation in a Phase 3 Study for Community Acquired Pneumonia, Including COVID-19, Influenzas and Bacterial Pneumonias REMAP-CAP is a global ...
PERTH, Australia – Melbourne, Australia-based Dimerix Ltd. saw its shares gain 66% on the news that its lead candidate, DMX-200, has been chosen to enter the global REMAP-CAP platform trial as a ...
PERTH, Australia – Melbourne, Australia-based Dimerix Ltd. saw its shares gain 66% on the news that its lead candidate, DMX-200, has been chosen to enter the global REMAP-CAP platform trial as a ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈